KIT p.Asp816Ala
Variant summary
The NM_000222.3(KIT):c.2447A>C (p.Asp816Ala) variant causes a missense change involving the alteration of a conserved nucleotide. The gene KIT is a known oncogene (CancerMine: 3 TSG, 792 oncogene, 258 driver citations). The gene KIT is a cancer driver gene (CancerMine: 3 TSG, 792 oncogene, 258 driver citations). The variant is absent from the gnomAD population database at sites with sufficient sequencing coverage. In-silico predictor (REVEL) classifies this variant as likely damaging/oncogenic. Splicing prediction tools (SpliceAI) predict no significant impact on normal splicing. The affected nucleotide is highly conserved across species (PhyloP 100-way vertebrate score: 9.22). No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar. A different missense at the same amino acid position has been reported as Pathogenic/Likely Pathogenic in ClinVar: p.D816H: Pathogenic (ClinVar VariationId 13863, 2 stars) Other variants at the same amino acid position have been reported in ClinVar (not pathogenic): p.D816= (synonymous): Conflicting_classifications_of_pathogenicity (ClinVar VariationId 286360); p.D816G: Uncertain_significance (ClinVar VariationId 1968176, 1 star); p.D816Y: Uncertain_significance (ClinVar VariationId 13860, 1 star) This exact variant is established as oncogenic in: CGI (Cancer Genome Interpreter). The variant position is a cancer hotspot (cancerhotspots.org): 22 samples carry this exact amino acid change out of 88 samples with a variant at this residue. The variant has been observed in cBioPortal in 5 samples across 5 studies and 2 cancer types; somatic enrichment level: SUPPORTING (Observed repeatedly in cBioPortal somatic datasets.).
Frequency
Consequence
NM_000222.3 missense
Scores
Clinical Significance
Conservation
Publications
- gastrointestinal stromal tumorInheritance: AD Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: ClinGen, PanelApp Australia, Labcorp Genetics (formerly Invitae), Orphanet, Genomics England PanelApp, Ambry Genetics
- piebaldismInheritance: AD Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: Orphanet, PanelApp Australia, Labcorp Genetics (formerly Invitae), Genomics England PanelApp, G2P, Ambry Genetics
- cutaneous mastocytosisInheritance: AD Classification: STRONG Submitted by: PanelApp Australia, Labcorp Genetics (formerly Invitae)
- mastocytosisInheritance: AD Classification: STRONG, MODERATE Submitted by: Genomics England PanelApp, Ambry Genetics
Genome browser will be placed here
Classification according to ACGS-UK Somatic Oncogenicity v2025
Our verdict: Pathogenic. The variant received 13 points.
| Apply | Criterion Code & Title / Strength | Rationale / Clinical Context | |
|---|---|---|---|
| O1Established oncogenic variant | CGI exact DNA-change oncogenic — Strong (O1); O1 contributing sources (4.0 pts): CGI (Cancer Genome Interpreter) | ||
| O3Absent or very rare in population | Absent or extremely rare in gnomAD (AC ≤ 2) — O3 moderate; GnomAD: AF = absent, AC = 0 — absent/extremely rare (O3 moderate [+2]) | ||
| O4Enriched in somatic variant database | Enriched in cBioPortal (pre-computed score ≥ 1.0) — Supporting (O4); cBioPortal: samples=5 | studies=5 | cancer types=2 | level=SUPPORTING | points=1.0 | reason: Observed repeatedly in cBioPortal somatic datasets. | ||
| O5Same location/impact as known oncogenic | Different AA at same residue with oncogenic evidence (or germline P/LP in TSG), or same AA change SCI Tier II Potential — Supporting (O5); ClinVar same-AA oncogenic/T1: false | ClinVar same-AA SCI tier: — | CGI same-AA oncogenic: false | TSG: false | ClinVar same-AA germline P/LP: false | CIViC LOF: false | ClinVar diff-AA oncogenic: true | ClinVar diff-AA germline P/LP: true | ||
| O6Computational evidence supports deleterious effect | Computational evidence supports a deleterious/oncogenic effect; Missense variant — primary computational scorer supports an oncogenic/deleterious effect | ||
| O7Mutational hotspot or critical domain | Strong hotspot (cancerhotspots.org): >50 total samples, ≥10 same AA change; Note: exclude MSK/TCGA-derived samples from cancerhotspots count to avoid double-counting with O4; cancerhotspots.org: total samples at AA position = 88, same AA change = 22; Exclude MSK/TCGA-derived samples from count to avoid double-counting with O4; UniProt domain: 0 pathogenic, 0 benign.; ±8 AA neighbourhood: 6 pathogenic, 0 benign (OR vs. background: 65.0); Variant does not impact splicing — splice-hotspot path not applicable |
Variant Effect in Transcripts
Automated classification analysis was done for transcript: NM_000222.3. You can select a different transcript below to see updated classification assignments.
RefSeq Transcripts
| Sel. | Gene / Transcript | Tags | HGVSc / HGVSp | Effect | Exon rank | Protein / UniProt |
|---|---|---|---|---|---|---|
KIT | MANE Select | c.2447A>C p.Asp816Ala | missense | Exon 17 of 21 | Prot: NP_000213.1 UniProt: | |
KIT | c.2450A>C p.Asp817Ala | missense | Exon 17 of 21 | Prot: NP_001372213.1 UniProt: | ||
KIT | c.2447A>C p.Asp816Ala | missense | Exon 17 of 21 | Prot: NP_001372219.1 UniProt: |
Ensembl Transcripts
| Sel. | Gene / Transcript | Tags | HGVSc / HGVSp | Effect | Exon rank | Protein / UniProt |
|---|---|---|---|---|---|---|
KIT | TSL:1MANE Select | c.2447A>C p.Asp816Ala | missense | Exon 17 of 21 | Prot: ENSP00000288135.6 UniProt: | |
KIT | TSL:1 | c.2435A>C p.Asp812Ala | missense | Exon 17 of 21 | Prot: ENSP00000390987.3 UniProt: | |
KIT | c.2450A>C p.Asp817Ala | missense | Exon 17 of 21 | Prot: ENSP00000509371.1 UniProt: |
Frequencies
Allele frequencies (AF), counts (AC/AN), homozygotes and coverage
| Source / population | AF | AC | Hom | AN | Coverage |
|---|---|---|---|---|---|
Global population databases 3 sources | |||||
GnomAD3 genomes | Cov:32 | ||||
GnomAD4 exome | Cov:30 | ||||
GnomAD4 genome | Cov:32 | ||||
ClinVar
Not reported inComputational Scores
| Algorithm | Calibrated pred. | Score | Prediction |
|---|---|---|---|
AlphaGenome AVI | Pathogenic | 28 | |
AlphaMissense | Pathogenic | 1.0 | |
BayesDel_addAF | Pathogenic | 0.40 | D |
BayesDel_noAF | Pathogenic | 0.34 | |
CADD | Pathogenic | 30 | |
DANN | Uncertain | 1.0 | |
DEOGEN2 | Pathogenic | 0.80 | D |
Eigen | Uncertain | 0.61 | |
Eigen_PC | Pathogenic | 0.67 | |
FATHMM_MKL | Pathogenic | 0.99 | D |
FuncVEP CTI | Pathogenic | 0.89 | |
GPN-Star LLR | N/A | -9.9 | |
GPN-Star score | N/A | 9.9 | |
LIST_S2 | Uncertain | 0.91 | D |
M_CAP | Uncertain | 0.14 | D |
MetaRNN | Pathogenic | 0.95 | D |
MetaSVM | Uncertain | 0.14 | D |
Mutation Taster | N/A | 0/100 | disease causing |
MutationAssessor | Benign | 0.23 | N |
PhyloP100 | Pathogenic | 9.2 | |
popEVE | Pathogenic | -5.1 | |
PrimateAI | Pathogenic | 0.83 | D |
PROVEAN | Pathogenic | -6.7 | D |
REVEL | Pathogenic | 0.93 | |
Sift | Uncertain | 0.0010 | D |
Sift4G | Uncertain | 0.0040 | D |
Varity_R | N/A | 0.96 | |
VESM-3B | Benign | -13 |
Splicing Scores
| Algorithm | Calibrated pred. | Score | Prediction |
|---|---|---|---|
Pangolin (max) | Benign | 0.0 | |
SpliceAI score (max) | Benign | 0.0 | Details are displayed if max score is > 0.2 |
Find out detailed SpliceAI scores and Pangolin per-transcript scores at
MaxEntScan Visualizer can be used to analyze the impact of this mutation on the neighboring sequence.